We Offer Worldwide Shipping
Login Wishlist

Benzalazine

$53

  • Brand : BIOFRON

  • Catalogue Number : BN-O1073

  • Specification : 98%(HPLC)

  • CAS number : 588-68-1

  • Formula : C14H12N2

  • Molecular Weight : 208.26

  • PUBCHEM ID : 5324610

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1073

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

208.26

Appearance

Botanical Source

Structure Type

Category

SMILES

C1=CC=C(C=C1)C=NN=CC2=CC=CC=C2

Synonyms

benzalazin/BENZALAZINE/Benzaldazine/N,N'-dibenzylidene-hydrazine/Eusolex 6653/Eusolex/Benzaldazin/1,4-diphenyl-2,3-diaza-1,3-butadiene/benzoaldehyde azine/1,2-dibenzylidene hydrazine/EUSOLEX T-S

IUPAC Name

(E)-N-[(E)-benzylideneamino]-1-phenylmethanimine

Density

0.98g/cm3

Solubility

Flash Point

138.3ºC

Boiling Point

318.3ºC at 760mmHg

Melting Point

92-93ºC(lit.)

InChl

InChl Key

CWLGEPSKQDNHIO-JOBJLJCHSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:588-68-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

16178729

Abstract

This review provides an overview of the drug discovery process used to identify, develop and characterize the first positive allosteric modulators of the metabotropic glutamate receptor (mGluR) subtype 5 (mGluR5). Discovery and optimization of three series of positive allosteric modulators are described, each using different approaches. The symmetric benzaldazine series was discovered and optimized from samples already existing in our sample collection without an active synthetic program to further elucidate SAR. This series yielded a family of highly selective pharmacological tools that produced positive, negative and neutral allosteric modulation of mGluR5 activity. The original compound in the benzamide series was discovered from screening and this series was optimized using an iterative library synthesis approach to explore SAR in each of three regions of the molecule. This series produced more potent positive allosteric mGluR5 modulators than the benzaldazine series which could be evaluated for their effect on mGluR5 in brain slice electrophysiological studies. The pyrazole series used a fragment library approach based on small structural motives from the benzamide series to discover lead compounds and establish SAR. This series produced still more potent positive allosteric mGluR5 modulators with improved pharmacokinetic and physical properties. These modulators showed efficacy in animal behavioral models in which other antipsychotic drugs were active. Evaluation of assay data in mathematical models of allosterism to constrain possible mechanisms of action is briefly discussed. Other reviews of this emerging field with different emphases have been published recently [1-3].

Title

Discovery of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 (mGluR5)

Author

David L Williams Jr 1, Craig W Lindsley

Publish date

2005

PMID

7848362

Abstract

The pharmacokinetic properties of benzalazine ((2-hydroxy-5-[(4-carboxyphenyl)azo]benzoic acid, CAS 64896-26-0), a new agent for the treatment of ulcerative colitis and Crohn’s disease of the large intestine, were investigated. From jejunal loops of rats in situ no noteworthy absorption of benzalazine was observed. All attempts to demonstrate metabolic conversion of benzalazine in mucosal homogenate of the small intestine of rats were without any success. In faecal suspensions, the half-life of the metabolic conversion of benzalazine was determined as 15 min and the formation of the metabolite 5-aminosalicylic acid (5-ASA) was demonstrated qualitatively. 72 h after single oral administration of 300 mg benzalazine/kg b.w. to rats, an average of 71.83% of the administered dose was recovered in urine and faeces. Only a small amount of unmetabolized benzalazine was excreted with urine and faeces (0.75% and 1.47% of the administered dose, respectively). The benzalazine metabolite 5-ASA and the 5-ASA metabolite acetyl-5-aminosalicylic acid (Ac-5-ASA) were excreted mainly with the faeces (29.22% and 20.66% of the administered dose, respectively) and only in small amounts with the urine (2.54% and 11.06% of the administered dose, respectively).

Title

Pharmacokinetic Studies of Benzalazine

Author

R Herzog 1, J Leuschner

Publish date

Dec-94

PMID

18636467

Abstract

Three azines, two of them doubly labeled with (15)N, have been studied by multinuclear magnetic resonance in solution and in the solid state. The spectral parameters obtained by iterative analyses have been compared with DFT/B3LYP calculated values (absolute shieldings and coupling constants). The agreement is generally good. Some anomalies have been discussed in relation to the structure of these compounds.

2008 John Wiley & Sons, Ltd.

Title

Experimental Measurements and Theoretical Calculations of the Chemical Shifts and Coupling Constants of Three Azines (Benzalazine, Acetophenoneazine and Cinnamaldazine)

Author

Artur M S Silva 1, Regina M S Sousa, Maria Luisa Jimeno, Fernando Blanco, Ibon Alkorta, Jose Elguero

Publish date

Sep-08


Description :

Empty ...